The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Wild-type p53 interacts with its negative regulators, which mainly include MDM2/4 (Fig. 1c-f), to maintain its low expression.190,191”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Further studies showed that MDM2 is an E3 ubiquitin ligase that directly ubiquitinates and targets the p53 protein for proteosomal degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“Mdm2-null mice are early embryonic lethal, losing viability preimplantation (Jones et al. 1995; Montes de Oca Luna et al. 1995; Chavez-Reyes et al. 2003).”
BackgroundSelf-citationMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04990.x · Cited by 879
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · cited 1×
“MDM4 (originally and often referred to as MDMX) was identified in a screen for p53 interacting proteins (Shvarts et al. 1996).”
BackgroundShangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
Self-citationDisruption of HAUSP gene stabilizes p53.
Cummins, J. M., Rago, C., Kohli, M., Kinzler, K. W., Lengauer, C., & Vogelstein, B. (2004) · Nature · doi:10.1038/nature02501 · Cited by 379
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292 · cited 1×
“TRIM24 is a p53-interacting protein identified through the affinity purification of a TAPtagged p53, from mouse embryonic stem cells (Allton et al. 2009).”
BackgroundThe multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo
Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., & Marine, J.-C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508476103 · Cited by 260
p53 is frequently mutated in Burkitt's lymphoma cell lines
Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H., & Crook, T. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07837.x · Cited by 254
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · cited 1×
“The development and advancement of specific p53:MDM4 inhibitors have clinical potential, with a number of small molecules already identified (Reed et al. 2010; Wang et al. 2011; Li and Lozano 2013).”
BackgroundInactivation of HAUSP in vivo modulates p53 function.
Kon, N., Kobayashi, Y., Li, M., Brooks, C. L., Ludwig, T., & Gu, W. (2010) · Oncogene · doi:10.1038/onc.2009.427 · Cited by 176
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Self-citationTissue-specific differences of p53 inhibition by Mdm2 and Mdm4
Grier, J. D., Xiong, S., Elizondo-Fraire, A. C., Parant, J. M., & Lozano, G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.192-198.2006 · Cited by 149
Self-citationA High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development
Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127
Self-citationBoesten, L. S. M., Zadelaar, S. M., De Clercq, S., Francoz, S., van Nieuwkoop, A., Biessen, E. A. L., Hofmann, F., Feil, S., Feil, R., Jochemsen, A. G., et al. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401973 · Cited by 70
Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo
De Clercq, S., Gembarska, A., Denecker, G., Maetens, M., Naessens, M., Haigh, K., Haigh, J. J., & Marine, J.-C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00330-10 · Cited by 35
Valentin-Vega, Y. A., Box, N., Terzian, T., & Lozano, G. (2009) · Differentiation · doi:10.1016/j.diff.2009.03.001 · Cited by 28
Self-citation
Research works printed but not linked: 95
- 2012, Prophylactic human papillomavirus vaccines: Past, present and future, Pathology, 44, 1, 10.1097/PAT.0b013e32834d7bd8 · DOI
- 10.1016/j.cell.2013.03.021 · DOI · Paper page
- 1993, mdm2 expression is induced by wild type p53 activity, EMBO J, 12, 461, 10.1002/j.1460-2075.1993.tb05678.x · DOI · Paper page
- 10.1038/ng.2279 · DOI · Paper page
- 10.1038/ng.619 · DOI · Paper page
- 10.1038/sj.onc.1210199 · DOI · Paper page
- 10.1016/j.cell.2004.11.022 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-0825 · DOI · Paper page
- 10.1016/j.tibs.2009.02.006 · DOI
- 10.1007/BF01535205 · DOI · Paper page
- 10.1038/nature07385 · DOI · Paper page
- 10.1038/nature10166 · DOI · Paper page
- 10.1038/nature11412 · DOI · Paper page
- 10.1038/nature12965 · DOI
- 2003, Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets, Cancer Res, 63, 8664
- 10.1101/cshperspect.a026310 · DOI
- 10.1002/rmv.431 · DOI
- 10.1016/0140-6736(92)90662-M · DOI · Paper page
- 10.2471/BLT.06.038414 · DOI · Paper page
- 10.1038/nature02514 · DOI · Paper page
- 1994, Alterations of the p53 gene in Epstein–Barr virus–associated immunodeficiency-related lymphomas, J Virol, 68, 1309, 10.1128/JVI.68.3.1309-1315.1994 · DOI
- 1992, Alterations of the p53 gene in nasopharyngeal carcinoma, J Virol, 66, 3768, 10.1128/JVI.66.6.3768-3775.1992 · DOI
- 10.1002/humu.22524 · DOI · Paper page
- 1991, Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line, EMBO J, 10, 1565, 10.1002/j.1460-2075.1991.tb07676.x · DOI · Paper page
- 10.1016/0092-8674(90)90186-I · DOI · Paper page
- 10.1073/pnas.94.12.6048 · DOI · Paper page
- 2003, p53-independent functions of MDM2, Mol Cancer Res, 1, 1027
- 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, l1
- 10.1101/cshperspect.a001032 · DOI
- 10.1158/0008-5472.CAN-03-1541 · DOI
- 10.1073/pnas.0508888102 · DOI · Paper page
- 10.1101/cshperspect.a026179 · DOI · Paper page
- 10.1371/journal.pgen.1002360 · DOI
- 10.1016/S0014-5793(00)01850-0 · DOI
- 10.1177/1947601910371979 · DOI
- 10.1073/pnas.1102309108 · DOI · Paper page
- 10.1038/nm1146 · DOI · Paper page
- 10.1200/JCO.2012.46.5740 · DOI · Paper page
- 10.4161/cbt.10.7.13445 · DOI
- 10.1016/j.jhep.2014.09.026 · DOI
- 10.1126/science.1200609 · DOI · Paper page
- 10.1073/pnas.95.26.15608 · DOI · Paper page
- 1993, Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene, Oncogene, 8, 3411
- 10.1002/1097-0142(20011215)92:12<3076::AID-CNCR10117>3.0.CO;2-D · doi:10.1002/1097-0142(20011215)92:12<3076::aid-cncr10117>3.0.co;2-d
- 10.1073/pnas.96.26.14973 · DOI · Paper page
- 10.4161/trns.2.5.16813 · DOI
- 10.1172/JCI44957 · DOI · Paper page
- 10.1038/278261a0 · DOI · Paper page
- 10.1016/j.cell.2004.11.006 · DOI · Paper page
- 10.1038/nature05194 · DOI · Paper page
- 10.1038/ng.3095 · DOI · Paper page
- 10.1016/S0092-8674(03)00193-4 · DOI · Paper page
- 10.1158/1078-0432.CCR-12-0053 · DOI · Paper page
- 10.1016/0092-8674(79)90293-9 · DOI · Paper page
- 10.1038/35074506 · DOI · Paper page
- 1992, p53 mutation in human nasopharyngeal carcinomas, Anticancer Res, 12, 1957
- 10.1016/j.ccr.2007.08.033 · DOI · Paper page
- 10.1677/erc.1.01223 · DOI
- 10.1128/MCB.23.2.462-473.2003 · DOI · Paper page
- 10.1172/JCI45784 · DOI
- 1996, Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus, Blood, 88, 645, 10.1182/blood.V88.2.645.bloodjournal882645 · DOI · Paper page
- 10.1002/cncr.24841 · DOI
- 10.1038/362857a0 · DOI · Paper page
- 10.1101/cshperspect.a001107 · DOI · Paper page
- 10.1038/25870 · DOI · Paper page
- 10.1101/gad.247452.114 · DOI · Paper page
- 10.1073/pnas.1102241108 · DOI · Paper page
- 10.1101/gad.227249.113 · DOI
- 10.1038/ng.2396 · DOI · Paper page
- 10.1128/JVI.01757-06 · DOI
- 10.1016/j.ccr.2006.10.010 · DOI · Paper page
- 10.1038/ng.2405 · DOI · Paper page
- 2013, Genome guardian p53 and viral infections, Rev Med Virol, 23, 213, 10.1002/rmv.1738 · DOI
- 10.1016/0092-8674(90)90409-8 · DOI · Paper page
- 10.1006/mgme.2000.3114 · DOI
- 10.1074/jbc.274.53.38189 · DOI · Paper page
- 10.1101/cshperspect.a026203 · DOI
- 10.1006/geno.1997.4775 · DOI
- 10.1038/nature13176 · DOI · Paper page
- 10.1016/S0014-5793(99)00254-9 · DOI · Paper page
- 10.1073/pnas.96.12.6937 · DOI · Paper page
- 10.1016/j.ccr.2010.05.026 · DOI · Paper page
- 10.1016/j.molmed.2006.11.002 · DOI · Paper page
- 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F · doi:10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f
- 10.1158/1535-7163.MCT-10-0581 · DOI · Paper page
- 10.1101/cshperspect.a026245 · DOI · Paper page
- 10.1309/AJCPLYU89XHSNHQO · DOI
- 10.1038/8991 · DOI · Paper page
- 10.1126/science.2157286 · DOI · Paper page
- 1997, Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene, Mol Med, 3, 441, 10.1007/BF03401691 · DOI · Paper page
- 10.1101/gad.7.7a.1126 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-1457 · DOI · Paper page
- 1993, Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53–MDM2 complexes, EMBO J, 12, 2799, 10.1002/j.1460-2075.1993.tb05941.x · DOI
- 10.1002/path.4368 · DOI
- 10.1016/j.urology.2003.11.011 · DOI
Cited by
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Eischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Heredia-Soto, V., Redondo, A., Berjón, A., Miguel-Martín, M., Díaz, E., Crespo, R., Hernández, A., Yébenes, L., Gallego, A., Feliu, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25098 · Cited by 33
Metadata
- Authors
- Wasylishen, A. R., & Lozano, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-06-21
- Volume
- 6
- Issue
- 8
- Pages
- a026211
- ISSN
- 2157-1422
- Cited by
- 123
- References
- 42
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.